NAD+ in Australia: a cellular-cofactor research guide

NAD+ in Australia. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell — a cellular-cofactor research compound referenced across sirtuin-pathway, mitochondrial-NAD+ and cellular-ageing research literature. Although catalogued alongside the research peptides, it is technically a dinucleotide, so it carries no amino-acid sequence. This guide is a research-reference summary for Australian researchers; it makes no anti-ageing, longevity-outcome, or human-use claim.

What NAD+ is

NAD+ is a central cofactor in cellular redox biology — the electron carrier that shuttles between its oxidised (NAD+) and reduced (NADH) forms in metabolism. In research it is studied less as a receptor ligand and more as a metabolic cofactor whose availability influences the activity of NAD+-consuming enzymes, principally the sirtuins and the PARPs. That cofactor role is why it sits in the longevity strand of the catalogue rather than among the receptor-targeted peptides.

Sirtuin-pathway and cellular-ageing research

NAD+’s role linking cellular metabolism, sirtuin and PARP activity, and age-related decline is surveyed authoritatively by Verdin (Science, 2015). The biosynthesis and salvage pathways, and the mechanistic basis by which NAD+ availability modulates sirtuin-dependent metabolic and mitochondrial function, are reviewed by Rajman and colleagues (Cell Metabolism, 2018). In pathway research NAD+ is referenced as a cofactor for the sirtuin (SIRT1, SIRT3 and related) enzymes, converging with mitochondrial-NAD+ and cellular-ageing research — as an in-vitro research tool, not a treatment.

NAD+ alongside MOTS-c and SS-31

Within the longevity category NAD+ is most-cited alongside MOTS-c (a mitochondrial-derived peptide) and SS-31 (a mitochondrial-membrane-targeting tetrapeptide). The three interrogate mitochondrial and cellular-ageing biology by different routes — cofactor availability, a genome-encoded peptide, and membrane targeting. The MOTS-c vs NAD+ comparison draws out the peptide-versus-cofactor distinction, and the SS-31 guide covers the membrane-targeting tool.

Two strengths, and why NAD+ needs light protection

NAD+ is stocked in 100mg and 500mg lyophilised vials — the 500mg vial the larger-batch workhorse most-cited across published protocols, the 100mg the lower-volume entry strength. NAD+ is light-sensitive, so research protocols typically note the light-protection step explicitly: store the lyophilised powder at −20°C protected from light, and once reconstituted with bacteriostatic water refrigerate at 2–8°C and use within the documented research window.

Identity, purity and compliance

Every batch of NAD+ is independently HPLC-tested by Janoshik before it is listed, with the certificate published on the product page and in the lab-reports library — real batch number, measured percentage, independently verifiable at janoshik.com. NAD+ is not TGA-approved and is not a therapeutic good; Elite AU Peptides makes no anti-ageing, longevity-outcome, or human-use claim, and supplies it strictly for in-vitro and laboratory research use only.